Thrombosis and haemostasis最新文献

{"title":"Identifying risk factors for left ventricular thrombus in patients with ischemic left ventricular aneurysm using cardiac MRI.","authors":"Yanfang Wu, Hui Wang, Zhiyan Wang, Chang Hua, Rang Xiong, Hao Fu, Qiang Lv, Lei Xu, Xin Du, Jian-Zeng Dong","doi":"10.1055/a-2536-8739","DOIUrl":"https://doi.org/10.1055/a-2536-8739","url":null,"abstract":"<p><strong>Background: </strong>Ischemic left ventricular (LV) aneurysm is associated with LV thrombus and subsequent embolic events. However, there is currently no evidence-based recommendation for anticoagulation in these patients.</p><p><strong>Objective: </strong>To determine the characteristics of LV aneurysms associated with a high risk of thrombus formation.</p><p><strong>Methods: </strong>This retrospective study included all hospitalized patients with ischemic LV aneurysm who underwent cardiac magnetic resonance (CMR) from September 2015 to June 2023. Baseline characteristics and CMR parameters were compared between patients with and without LV thrombus. Factors associated with LV thrombus were identified using univariable and multivariable logistic regression analyses.</p><p><strong>Results: </strong>Among the 317 patients included in this study, 88 (27.8%) had LV thrombus. Patients with LV thrombus demonstrated a higher prevalence of heart failure, lower left ventricular ejection fraction, and greater volume, mass, and global extent of late gadolinium enhancement (LGE). They also exhibited distinct LV aneurysm characteristics, such as a larger maximum transverse dimension (maximum width), a wider aneurysm neck, and a higher aneurysm shape index (ratio of maximum length to neck width). Multivariable logistic regression analyses identified aneurysm neck width (OR 1.33 per 5 mm, 95% CI 1.00-1.77, P = 0.047), shape index (OR 1.63 per 20%, 95% CI 1.23-2.16, P = 0.001), and LGE global extent > 50% (OR 6.58, 95% CI 3.04-14.27, P < 0.001) as significant predictors of LV thrombus.</p><p><strong>Conclusions: </strong>A wider aneurysm neck, a higher aneurysm shape index, and LGE global extent > 50% are associated with LV thrombus in patients with ischemic LV aneurysm.</p>","PeriodicalId":23036,"journal":{"name":"Thrombosis and haemostasis","volume":" ","pages":""},"PeriodicalIF":5.0,"publicationDate":"2025-02-11","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143399962","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Influence of Direct Oral Anticoagulant Levels and Thrombin Generation on Postoperative Bleeding [SONAR]: A Nested Case-Control Study.","authors":"Joseph R Shaw, Na Li, Matthieu Grussé, Patrick Van Dreden, Melanie St John, Joanne Nixon, Alex C Spyropoulos, Sam Schulman, Jerrold H Levy, Marc Carrier, James D Douketis","doi":"10.1055/a-2521-0923","DOIUrl":"10.1055/a-2521-0923","url":null,"abstract":"<p><strong>Background: </strong> A direct oral anticoagulant (DOAC) concentration threshold above which an impact on surgical hemostasis starts to occur is unknown. Thrombin generation assays (TGAs) provide a measure of the coagulation phenotype. This study aimed to determine whether preoperative TGA parameters are associated with postoperative bleeding, and whether this is partly due to residual DOAC levels.</p><p><strong>Materials and methods: </strong> We conducted a nested case-control study using samples from apixaban/rivaroxaban-treated patients with atrial fibrillation from the PAUSE (Perioperative Anticoagulation Use for Surgery Evaluation) perioperative study. Cases were participants with postoperative major or clinically relevant nonmajor bleeding; controls were participants without bleeding. DOAC levels were measured using a chromogenic anti-Xa assay (BIOPHEN DiXaI; rivaroxaban/apixaban calibrators). TGA parameters were measured using calibrated automated thrombography.Generalized linear mixed models and causal mediation analyses were used to evaluate the relationship between DOAC levels, TGA parameters, and bleeding.</p><p><strong>Results: </strong> Forty eight cases were matched to 474 controls. Residual DOAC levels were higher in cases than controls (p¼0.03) and each TGA parameter was correlated with residual DOAC levels (p<0.05). A longer lag time (LT; odds ratio [OR]¼1.319 per minute [95% confidence interval [CI]: 1.077-1.617]) and time-to-peak (TTP; OR¼1.154 per minute [95% CI: 1.028-1.296]) were associated with an increased odds of bleeding; higher peak (OR¼0.994 per nM [95% CI: 0.989-0.998]) and mean velocity rate index (mVRI; OR¼0.986 per nM/min [95% CI: 0.976-0.996]) were associated with a lower odds of bleeding. The effect of apixaban/rivaroxaban levels on bleeding was mediated by altered TGA parameters (LT, TTP, peak, mVRI).</p><p><strong>Conclusion: </strong> These findings support a measurable effect from low residual DOAC levels on thrombin generation and suggest a causal contribution of both toward bleeding.</p>","PeriodicalId":23036,"journal":{"name":"Thrombosis and haemostasis","volume":" ","pages":""},"PeriodicalIF":5.0,"publicationDate":"2025-02-11","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143012017","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Differences in the outcome of cancer-associated thrombosis depending on cancer type.","authors":"Ramón Lecumberri, María Marcos, Jose Hermida, Pedro Ruiz-Artacho","doi":"10.1055/a-2535-7400","DOIUrl":"https://doi.org/10.1055/a-2535-7400","url":null,"abstract":"<p><p>The outcome of venous thromboembolism (VTE) in patients with cancer is worse than in patient without cancer, with higher risk of recurrences, bleeding and death. However, these risks appear to vary depending on the cancer type. While in some tumors the risk of recurrences outweighs the risk of bleeding, in others the risk of major bleeding during the anticoagulation markedly exceeds the risk of a recurrent event. Balancing these risks could be helpful to tailor the management of cancer-associated thrombosis (CAT) and improve outcomes. In this article, published data from recent randomized clinical trials (RCT) as well as from some large registries that have reported separated outcomes of CAT depending on cancer type were reviewed. A careful balance of the risk of recurrences and major bleeding events could provide useful insights for clinicians for individualizing treatment strategies in order to improve the outcomes of CAT, as well as for the design of future clinical trials.</p>","PeriodicalId":23036,"journal":{"name":"Thrombosis and haemostasis","volume":" ","pages":""},"PeriodicalIF":5.0,"publicationDate":"2025-02-10","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143391845","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Inflammatory and Bleeding Risks on Clinical Outcomes in Acute Coronary Syndrome Patients Undergoing Percutaneous Coronary Intervention.","authors":"Yixuan Duan, Miaohan Qiu, Kun Na, Daoshen Liu, Shangxun Zhou, Ying Xu, Zizhao Qi, Haiwei Liu, Kai Xu, Xiaozeng Wang, Jing Li, Yi Li, Yaling Han","doi":"10.1055/a-2531-3268","DOIUrl":"https://doi.org/10.1055/a-2531-3268","url":null,"abstract":"<p><p>Objective This study aimed to evaluate the impact of systemic inflammation burden using high-sensitivity C-reactive protein (hsCRP) and long-term prognosis in acute coronary syndrome (ACS) patients undergoing percutaneous coronary intervention (PCI) stratified by bleeding risk status. Methods Consecutive patients admitted for ACS and who received PCI between March 2016 and March 2022 were enrolled in the analysis. Elevated systemic inflammation was defined as hsCRP>2 mg/L, and high bleeding risk (HBR) was defined the Academic Research Consortium (ARC)-HBR criteria. The primary outcome was ischemic events at 12 months, composed of cardiac death, myocardial infarction, and/or stroke. The main secondary outcomes included all-cause death, and Bleeding Academic Research Consortium (BARC) types 2, 3, and 5 bleeding and types 3, and 5 bleeding. Results Of 15,013 patients, 4606 (30.7%) were qualified as HBR and 8395 (55.9%) had hsCRP>2 mg/L. Elevated hsCRP were consistently associated with higher risk of ischemic events in both HBR (adjusted hazard ratio [aHR]: 1.20; 95% confidence interval [CI]: 0.91-1.58) and non-HBR (aHR: 1.34; 95% CI: 1.01-1.78) subgroups (P interaction=0.755). Although the bleeding events incidence was higher in HBR patients, an elevated hsCRP level was not associated with bleeding events regardless of HBR status. Restricted cubic spline regression represented an inverse J-shaped relation between hsCRP and non-HBR for ischemic events (P nonlinearity <0.001) and all-cause death (P nonlinearity = 0.003). Conclusion Regardless of HBR status, high levels of hsCRP were associated with an increased risk of ischemic events and all-cause death in ACS patients following PCI, but not for bleeding.</p>","PeriodicalId":23036,"journal":{"name":"Thrombosis and haemostasis","volume":" ","pages":""},"PeriodicalIF":5.0,"publicationDate":"2025-02-04","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143190719","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Utility of sepsis-induced coagulopathy among disseminated intravascular coagulation diagnostic criteria: A multicenter retrospective validation study.","authors":"Satoshi Gando, Takeshi Wada, Kazuma Yamakawa, Toshikazu Abe, Seitato Fujishima, Shigeki Kushimoto, Toshihiko Mayumi, Hiroshi Ogura, Daizoh Saitoh, Atsushi Shiraishi, Yutaka Umemura, Yasuhiro Otomo","doi":"10.1055/a-2530-7553","DOIUrl":"https://doi.org/10.1055/a-2530-7553","url":null,"abstract":"<p><strong>Background: </strong>The criteria for diagnosing sepsis-induced coagulopathy (SIC) may overlap with those of Japanese Association for Acute Medicine (JAAM) disseminated intravascular coagulation (DIC). We aimed to determine if the diagnostic criteria for SIC overlap with those for the JAAM DIC diagnosis of International Society on Thrombosis and Haemostasis (ISTH) DIC and whether patients have the same prognosis when diagnosed using these criteria.</p><p><strong>Methods: </strong>This multicenter retrospective study included patients with sepsis diagnosed using the JAAM and ISTH DIC and SIC criteria on days 1 and 4. The established ISTH DIC criteria was reference standard for primary outcome that compared the characteristics of SIC and JAAM DIC. Secondary outcomes were multiple organ dysfunction syndrome (MODS), ventilator- and intensive care unit-free days, and in-hospital mortality.</p><p><strong>Results: </strong>A total of 1,438 patients were included in this study. On day 1, the JAAM DIC and SIC criteria diagnosed almost all patients with ISTH DIC (98% and 94%, respectively), predicting ISTH DIC (area under the receiver operating curve [AUC]: 0.740 vs. 0.752, P = 0.523) and MODS (AUC: 0.686 vs. 0.697, P = 0.546) on day 4 and progressing to ISTH DIC in the same proportion (28.6 vs. 30.1%, P = 0.622). There were no differences in survival probabilities (P = 0.196) or secondary outcomes between patients diagnosed using JAAM DIC and SIC criteria on day 1.</p><p><strong>Conclusion: </strong>SIC and JAAM DIC diagnoses were equal among patients with sepsis, suggesting that SIC criteria add little to current DIC scoring systems.</p>","PeriodicalId":23036,"journal":{"name":"Thrombosis and haemostasis","volume":" ","pages":""},"PeriodicalIF":5.0,"publicationDate":"2025-02-03","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143123680","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Effect of Oral Anticoagulants in Atrial Fibrillation Patients with Polypharmacy: A Meta-analysis.","authors":"Yuxiang Zheng, Siyuan Li, Xiao Liu, Gregory Y H Lip, Linjuan Guo, Wengen Zhu","doi":"10.1055/s-0043-1770724","DOIUrl":"10.1055/s-0043-1770724","url":null,"abstract":"<p><strong>Background: </strong> The aim of the present meta-analysis was to evaluate the effectiveness and safety of non-vitamin K antagonist oral anticoagulants (NOACs) versus vitamin K antagonists (VKAs) in atrial fibrillation (AF) patients with polypharmacy.</p><p><strong>Methods and results: </strong> Randomized controlled trials or observational studies reporting the data of NOACs versus VKAs among AF patients with polypharmacy were included. The search was performed in the PubMed and Embase databases up to November 2022. A total of 12 studies involving 767,544 AF patients were included. For the primary outcomes, the use of NOACs compared with VKAs was significantly associated with a reduced risk of stroke or systemic embolism in AF patients with moderate polypharmacy (hazard ratio [HR]: 0.77 [95% confidence interval [CI]: 0.69-0.86]) and severe polypharmacy (HR: 0.76 [95% CI: 0.69-0.82]), but there was no significant difference in major bleeding (moderate polypharmacy: HR: 0.87 [95% CI: 0.74-1.01]; severe polypharmacy: HR: 0.91 [95% CI: 0.79-1.06]) between the two groups. In secondary outcomes, there were no differences in the rates of ischemic stroke, all-cause death, and gastrointestinal bleeding between the NOAC- and VKA- users, but NOAC users had a reduced risk of any bleeding compared with VKA- users. Compared with VKAs, the risk of intracranial hemorrhage was reduced in NOAC- users with moderate polypharmacy but not severe polypharmacy.</p><p><strong>Conclusion: </strong> In patients with AF and polypharmacy, NOACs showed advantages over VKAs in stroke or systemic embolism and any bleeding, and were comparable to VKAs for major bleeding, ischemic stroke, all-cause death, intracranial hemorrhage, and gastrointestinal bleeding.</p>","PeriodicalId":23036,"journal":{"name":"Thrombosis and haemostasis","volume":" ","pages":"166-177"},"PeriodicalIF":5.0,"publicationDate":"2025-02-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"9744417","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Novel Insights into the Aortic Mechanical Properties of Mice Modeling Hereditary Aortic Diseases.","authors":"Nicolo Dubacher, Kaori Sugiyama, Jeffrey D Smith, Vanessa Nussbaumer, Máté Csonka, Szilamér Ferenczi, Krisztina J Kovács, Sylvan M Caspar, Lisa Lamberti, Janine Meienberg, Hiromi Yanagisawa, Mary B Sheppard, Gabor Matyas","doi":"10.1055/s-0044-1787957","DOIUrl":"10.1055/s-0044-1787957","url":null,"abstract":"<p><strong>Objective: </strong> Hereditary aortic diseases (hADs) increase the risk of aortic dissections and ruptures. Recently, we have established an objective approach to measure the rupture force of the murine aorta, thereby explaining the outcomes of clinical studies and assessing the added value of approved drugs in vascular Ehlers-Danlos syndrome (vEDS). Here, we applied our approach to six additional mouse hAD models.</p><p><strong>Material and methods: </strong> We used two mouse models (<i>Fbn1C1041G</i> and <i>Fbn1mgR</i> ) of Marfan syndrome (MFS) as well as one smooth-muscle-cell-specific knockout (SMKO) of <i>Efemp2</i> and three CRISPR/Cas9-engineered knock-in models (<i>Ltbp1</i>, <i>Mfap4</i>, and <i>Timp1</i>). One of the two MFS models was subjected to 4-week-long losartan treatment. Per mouse, three rings of the thoracic aorta were prepared, mounted on a tissue puller, and uniaxially stretched until rupture.</p><p><strong>Results: </strong> The aortic rupture force of the SMKO and both MFS models was significantly lower compared with wild-type mice but in both MFS models higher than in mice modeling vEDS. In contrast, the <i>Ltbp1</i>, <i>Mfap4</i>, and <i>Timp1</i> knock-in models presented no impaired aortic integrity. As expected, losartan treatment reduced aneurysm formation but surprisingly had no impact on the aortic rupture force of our MFS mice.</p><p><strong>Conclusion: </strong> Our read-out system can characterize the aortic biomechanical integrity of mice modeling not only vEDS but also related hADs, allowing the aortic-rupture-force-focused comparison of mouse models. Furthermore, aneurysm progression alone may not be a sufficient read-out for aortic rupture, as antihypertensive drugs reducing aortic dilatation might not strengthen the weakened aortic wall. Our results may enable identification of improved medical therapies of hADs.</p>","PeriodicalId":23036,"journal":{"name":"Thrombosis and haemostasis","volume":" ","pages":"142-152"},"PeriodicalIF":5.0,"publicationDate":"2025-02-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11737803/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141477499","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Venous Thromboembolism Prophylaxis after Hematopoietic Cell Transplantation: Still a Challenge for Hematologists and Hemostasiologists.","authors":"Paola Ranalli, Hugo Ten Cate","doi":"10.1055/a-2434-5010","DOIUrl":"10.1055/a-2434-5010","url":null,"abstract":"","PeriodicalId":23036,"journal":{"name":"Thrombosis and haemostasis","volume":" ","pages":"163-165"},"PeriodicalIF":5.0,"publicationDate":"2025-02-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11785426/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142376079","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Vaccine-Induced Immune Thrombotic Thrombocytopenia Two Years Later: Should It Still Be on the Scientific Agenda?","authors":"Eleonora Petito, Paolo Gresele","doi":"10.1055/a-2107-0891","DOIUrl":"10.1055/a-2107-0891","url":null,"abstract":"<p><p>Vaccine-induced immune thrombotic thrombocytopenia (VITT) was recognized around 2 years ago, at the beginning of the anti-SARS-CoV-2 (severe acute respiratory syndrome coronavirus 2) vaccination campaign, as a rare but life-threatening complication of adenoviral vector vaccines. Two years later, the coronavirus disease 2019 (COVID-19) pandemic has been tamed, although not defeated, and the vaccines provoking VITT have been abandoned in most high-income countries, thus why should we still speak about VITT? Because a significant fraction of the world population has not been vaccinated yet, especially in low/middle-income countries that can only afford adenoviral vector-based vaccines, because the adenoviral vector platform is being used for the development of a large series of new vaccines for other transmissible diseases, and lastly because there are some clues suggesting that VITT may not be exclusive to anti-SARS-CoV-2 vaccines. Therefore, a deep understanding of this new syndrome is highly warranted as well as the awareness that we still miss some crucial insight into its pathophysiology and on some aspects of its management. This snapshot review aims to portray our knowledge on VITT, focusing on its clinical presentation, pathophysiological insight, diagnostic and management strategies, and to pinpoint the main unmet needs, highlighting the aspects on which research should focus in the near future.</p>","PeriodicalId":23036,"journal":{"name":"Thrombosis and haemostasis","volume":" ","pages":"97-107"},"PeriodicalIF":5.0,"publicationDate":"2025-02-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"9946466","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Venous Thromboembolism Post-allogeneic Hematopoietic Cell Transplant: Risk Factors, Incidence, and Outcomes.","authors":"Lauren M Granat, Hong Li, Mariah Ondeck, Bennet Osantowski, Chana Peysin, Mailey Wilks, Christina Ferraro, Ronald Sobecks, Dana Angelini, Betty K Hamilton","doi":"10.1055/a-2365-8883","DOIUrl":"10.1055/a-2365-8883","url":null,"abstract":"<p><strong>Background: </strong> Venous thromboembolism (VTE) is a well-documented complication of both solid and hematologic malignancies, but there are fewer data on allogeneic hematopoietic cell transplant (HCT) recipients. Therefore, we studied the incidence, risk factors, and impact of VTE on post-HCT outcomes in a contemporary cohort.</p><p><strong>Methods: </strong> We retrospectively reviewed patients who underwent allogeneic HCT between January 2014 and August 2019 to identify patients with post-HCT VTE. Patient, disease, and transplant-related risk factors for VTE were investigated using competing risk analysis.</p><p><strong>Results: </strong> A total of 431 patients were included in this study. Median (interquartile range [IQR]) age in years was 59 (46-65) at transplant. The most common indication for transplant was acute myelogenous leukemia (49.4%). Within our cohort, 64 patients (14.8%) developed post-HCT VTE with a median (IQR) follow-up time of 24.6 (8.4-47.1) months. The cumulative incidence of VTE was 4.2% at 6 months, 9.0% at 12 months, 12.6% at 24 months, and 13.8% at 36 months. In multivariable analysis, older age (hazard ratio [HR] per 10-year increase: 1.36, 95% confidence interval [CI]: 1.09-1.70), history of VTE (HR: 1.95, 95% CI: 1.09-3.49), and grade 2-4 acute graft versus host disease (GVHD; HR: 1.75, 95% CI: 1.05-2.94) were independently associated with VTE. VTE was significantly associated with an increased risk of nonrelapse mortality (NRM; HR: 4.09, 95% CI: 2.47-6.74) and decreased overall survival (OS; HR: 2.19, 95% CI: 1.48-3.24).</p><p><strong>Conclusion: </strong> VTE is an important complication after allogeneic HCT and is significantly associated with increased NRM and decreased OS. Older patients, those with prior VTE, and patients with acute GVHD are at increased risk for development of VTE after HCT.</p>","PeriodicalId":23036,"journal":{"name":"Thrombosis and haemostasis","volume":" ","pages":"155-162"},"PeriodicalIF":5.0,"publicationDate":"2025-02-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141620925","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}